Be the first to like this
Generic and innovative drugs market in Poland 2012- Development forecasts for 2012-2014Generic and innovative drugs market in Poland 2012, Development forecasts for 2012-2014 is a comprehensive source of data and analysis focused on recent and impending changes in the market resulting from the January 2012 reimbursement act. This legislation has the power to change the framework of the Polish pharmaceutical sector, particularly the generic and innovative drug segments, and the report guides readers to a thorough understanding of the act's provisions and offers ways for companies to adapt to the new rules and preserve their profits.In addition to providing complete forecasts for these two segments, as well as for the overall pharmaceutical industry in Poland to 2014, this document supplies data on the market share occupied by these two drug categories in terms of value and volume, and prices of innovative drugs and generics in Poland and as compared to other markets. It simplifies complex issues such as the Polish reimbursement process, upcoming changes to reimbursement and the lists of reimbursed and non-reimbursed drugs, fixed outlays of the National Health fund, payment structures and operations of therapies vs. medications.Topics essential to manufacturers and producers of generic and innovative drugs include: evaluation of the effects of the new act on major market players, suggested methods of limiting potentially harmful effects to businesses, changes in prices of top products in these categories, changes to reimbursements and refund status, role of the AOTM and other agencies in the reimbursement decision process, recent price negotiations with government agencies, funding limits and fixed prices and margins. Generic and innovative drugs market in Poland 2012, Development forecasts for 2012-2014 contains vital data on the current market, explanation of all changes due to new regulation and projects for the future of this important part of the pharmaceutical industry.